Answers are grounded in this paper and cite their sources.
With the advent of small-molecule immune modulators, recombinant fusion proteins, and monoclonal antibodies, treatment options for patients with rheumatic diseases are now broad. These agents carry significant risks and an individualized approach to each patient, balancing known risks and benefits, remains the most prudent course. This review summarizes the available immunosuppressant treatments, discusses their perioperative implications, and provides recommendations for their perioperative management.
No takes yet. Share an insight, caveat, or question.
Koh et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: